Julun Yang

212 Daguan Rd
Kunming, 650032, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

KRAS mutations promote PD-L1-mediated immune escape by ETV4 in lung adenocarcinoma.

KRAS mutations promote PD-L1-mediated immune escape by ETV4 in lung adenocarcinoma.

Journal: Translational oncology

Published: March 30, 2025

KRAS mutation promotes immune escape of lung adenocarcinoma via ZNF24/SLC7A5/PD-L1 axis.

KRAS mutation promotes immune escape of lung adenocarcinoma via ZNF24/SLC7A5/PD-L1 axis.

Journal: BMC cancer

Published: September 08, 2024

RGD-p21Ras-scFv expressed prokaryotically on a pilot scale inhibits ras-driven colorectal cancer growth by blocking p21Ras-GTP.

RGD-p21Ras-scFv expressed prokaryotically on a pilot scale inhibits ras-driven colorectal cancer growth by blocking p21Ras-GTP.

Journal: BMC cancer

Published: March 07, 2023

Recent advances in the tumor-penetrating peptide internalizing RGD for cancer treatment and diagnosis.

Recent advances in the tumor-penetrating peptide internalizing RGD for cancer treatment and diagnosis.

Journal: Drug development research

Published: November 29, 2022

ZNF24 regulates the progression of KRAS mutant lung adenocarcinoma by promoting SLC7A5 translation.

ZNF24 regulates the progression of KRAS mutant lung adenocarcinoma by promoting SLC7A5 translation.

Journal: Frontiers in oncology

Published: September 13, 2022

BR2 cell penetrating peptide effectively delivers anti-p21Ras scFv to tumor cells with ganglioside expression for therapy of ras-driven tumor.

BR2 cell penetrating peptide effectively delivers anti-p21Ras scFv to tumor cells with ganglioside expression for therapy of ras-driven tumor.

Journal: PloS one

Published: December 27, 2021

Inhibition of human lung cancer cells by anti-p21Ras scFv mediated by the activatable cell-penetrating peptide.

Inhibition of human lung cancer cells by anti-p21Ras scFv mediated by the activatable cell-penetrating peptide.

Journal: Anti-cancer drugs

Published: August 02, 2021

Correction to: RGD4C peptide mediates anti-p21Ras scFv entry into tumor cells and produces an inhibitory effect on the human colon cancer cell line SW480.

Correction to: RGD4C peptide mediates anti-p21Ras scFv entry into tumor cells and produces an inhibitory effect on the human colon cancer cell line SW480.

Journal: BMC cancer

Published: April 08, 2021

RGD4C peptide mediates anti-p21Ras scFv entry into tumor cells and produces an inhibitory effect on the human colon cancer cell line SW480.

RGD4C peptide mediates anti-p21Ras scFv entry into tumor cells and produces an inhibitory effect on the human colon cancer cell line SW480.

Journal: BMC cancer

Published: October 14, 2020

The immunoreactivity of the anti-p21Ras single-chain fragment variant KGH-R1 and its predicted binding sites to p21Ras.

The immunoreactivity of the anti-p21Ras single-chain fragment variant KGH-R1 and its predicted binding sites to p21Ras.

Journal: Immunotherapy

Published: July 16, 2020

An interobserver reproducibility analysis of size-set semiautomatic counting for Ki67 assessment in breast cancer.

An interobserver reproducibility analysis of size-set semiautomatic counting for Ki67 assessment in breast cancer.

Journal: Breast (Edinburgh, Scotland)

Published: August 20, 2019

p53 mutation regulates PKD genes and results in co-occurrence of PKD and tumorigenesis.

p53 mutation regulates PKD genes and results in co-occurrence of PKD and tumorigenesis.

Journal: Cancer biology & medicine

Published: May 24, 2019

Showing 1-12 of 20

Last Updated: 09/26/2026